Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

3,624 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Neoadjuvant nivolumab plus chemotherapy in resectable non-small-cell lung cancer in Japanese patients from CheckMate 816.
Mitsudomi T, Ito H, Okada M, Sugawara S, Shio Y, Tomii K, Okami J, Sakakura N, Kubota K, Takamochi K, Atagi S, Tsuboi M, Oizumi S, Ikeda N, Ohde Y, Ntambwe I, Mahmood J, Cai J, Tanaka F. Mitsudomi T, et al. Among authors: kubota k. Cancer Sci. 2024 Feb;115(2):540-554. doi: 10.1111/cas.16030. Epub 2023 Dec 14. Cancer Sci. 2024. PMID: 38098261 Free PMC article. Clinical Trial.
Standard versus low-dose nab-paclitaxel in previously treated patients with advanced non-small cell lung cancer: A randomized phase II trial (JMTO LC14-01).
Takeuchi S, Kubota K, Sugawara S, Teramukai S, Noro R, Fujikawa K, Hirose T, Atagi S, Minami S, Iida S, Kuraishi H, Aiba T, Minegishi Y, Matsumoto M, Seike M, Gemma A, Kawahara M; Japan-Multinational Trial Organization (JMTO). Takeuchi S, et al. Among authors: kubota k. Cancer Med. 2023 Apr;12(8):9133-9143. doi: 10.1002/cam4.5652. Epub 2023 Feb 21. Cancer Med. 2023. PMID: 36807519 Free PMC article. Clinical Trial.
Quality of life with docetaxel plus cisplatin versus paclitaxel plus carboplatin in patients with completely resected non-small cell lung cancer: quality of life analysis of TORG 0503.
Matsuda A, Yamaoka K, Kunitoh H, Seto T, Tsuboi M, Ohira T, Maruyama R, Okamoto H, Kubota K. Matsuda A, et al. Among authors: kubota k. Qual Life Res. 2023 Sep;32(9):2629-2637. doi: 10.1007/s11136-023-03424-y. Epub 2023 May 1. Qual Life Res. 2023. PMID: 37126140 Clinical Trial.
Carboplatin and irinotecan (CI) vs. carboplatin and etoposide (CE) for the treatment of extended-stage small-cell lung cancer in an elderly population: A phase II/III randomized control trial.
Shimokawa T, Okamoto H, Machida R, Misumi Y, Hosomi Y, Yoneshima Y, Tanaka H, Okishio K, Simizu J, Goto K, Akamatsu H, Kubota K, Nakagawa K, Horinouchi H, Ando M, Kataoka T, Ohe Y. Shimokawa T, et al. Among authors: kubota k. Lung Cancer. 2023 Jul;181:107195. doi: 10.1016/j.lungcan.2023.107195. Epub 2023 Apr 22. Lung Cancer. 2023. PMID: 37156212 Free article. Clinical Trial.
A Phase Ⅱ Study of Ubenimex Combined With Pembrolizumab, Nab-Paclitaxel, and Carboplatin for Previously Untreated Advanced Squamous Non-Small-Cell Lung Cancer: TORG2241 (UBE-Q).
Nakamichi S, Kubota K, Matsuyama K, Misumi T, Kozuki T, Sugawara S, Naoki K, Kobayashi N, Shukuya T, Shimokawa T, Ishihara M, Wakui H, Hosomi Y, Tanaka H, Saito H, Hosokawa S, Takiguchi Y, Kasai T, Nokihara H, Morita R, Aono H, Furuya N, Okamoto H. Nakamichi S, et al. Among authors: kubota k. Clin Lung Cancer. 2024 Jan;25(1):85-90. doi: 10.1016/j.cllc.2023.09.006. Epub 2023 Oct 4. Clin Lung Cancer. 2024. PMID: 37981477 Clinical Trial.
Phase II Study of Durvalumab Immediately after Completion of Chemoradiotherapy in Unresectable Stage III Non-small Cell Lung Cancer: TORG1937 (DATE Study).
Nakamichi S, Kubota K, Misumi T, Kondo T, Murakami S, Shiraishi Y, Imai H, Harada D, Isobe K, Itani H, Takata S, Wakui H, Misumi Y, Ikeda S, Asao T, Furuya N, Hosokawa S, Kobayashi Y, Takiguchi Y, Okamoto H. Nakamichi S, et al. Among authors: kubota k. Clin Cancer Res. 2024 Mar 15;30(6):1104-1110. doi: 10.1158/1078-0432.CCR-23-2568. Clin Cancer Res. 2024. PMID: 38165684 Free PMC article. Clinical Trial.
The IASLC/ITMIG thymic malignancies staging project: development of a stage classification for thymic malignancies.
Detterbeck FC, Asamura H, Crowley J, Falkson C, Giaccone G, Giroux D, Huang J, Kim J, Kondo K, Lucchi M, Marino M, Marom EM, Nicholson A, Okumura M, Ruffini E, van Schil P, Stratton K; Staging and Prognostic Factors Committee; Members of the Advisory Boards; Participating Institutions of the Thymic Domain. Detterbeck FC, et al. J Thorac Oncol. 2013 Dec;8(12):1467-73. doi: 10.1097/JTO.0000000000000017. J Thorac Oncol. 2013. PMID: 24389429 Free article.
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial.
Mok TSK, Wu YL, Kudaba I, Kowalski DM, Cho BC, Turna HZ, Castro G Jr, Srimuninnimit V, Laktionov KK, Bondarenko I, Kubota K, Lubiniecki GM, Zhang J, Kush D, Lopes G; KEYNOTE-042 Investigators. Mok TSK, et al. Among authors: kubota k. Lancet. 2019 May 4;393(10183):1819-1830. doi: 10.1016/S0140-6736(18)32409-7. Epub 2019 Apr 4. Lancet. 2019. PMID: 30955977 Clinical Trial.
3,624 results